Department of Biomedical Engineering, Columbia University, New York, NY 10032, USA.
Ludwig Boltzmann Institute of Experimental and Clinical Traumatology, Austrian Cluster for Tissue Regeneration, Vienna A-1200, Austria.
Biomaterials. 2017 Sep;139:202-212. doi: 10.1016/j.biomaterials.2017.05.045. Epub 2017 May 31.
Bone has innate ability to regenerate following injury. However, large and complex fractures exceed bone's natural repair capacity and result in non-unions, requiring external intervention to facilitate regeneration. One potential treatment solution, tissue-engineered bone grafts, has been dominated by recapitulating intramembranous ossification (bone formation by osteoblasts), although most serious bone injuries heal by endochondral ossification (bone formation by remodeling of hypertrophic cartilaginous anlage). The field has demonstrated that using endochondral ossification-based strategies can lead to bone deposition. However, stem cell differentiated hypertrophic chondrocytes, the key cell type in endochondral ossification, have not been studied for long bone defect repair. With translation in mind, we created tissue-engineered grafts using human adipose stem cells (ASC), a clinically relevant stem cell source, differentiated into hypertrophic chondrocytes in decellularized bone scaffolds, and implanted these grafts into critical-size femoral defects in athymic rats. Over 12 weeks of implantation, these grafts were compared to acellular scaffolds and grafts engineered using ASC-derived osteoblasts. Grafts engineered using hypertrophic chnodrocytes recapitulated endochondral ossification, as evidenced by the expression of genes and proteins associated with bone formation. Markedly enhanced bone deposition was associated with extensive bone remodeling and the formation of bone marrow, and with the presence of pro-regenerative M2 macrophages within the hypertrophic grafts. As a result, hypertrophic chondrocyte grafts bridged 7/8 defects, as compared to only 1/8 for osteoblast grafts and 3/8 acellular scaffolds. These data suggest that ASC-derived hypertrophic chondrocytes in osteogenic scaffolds can improve long bone repair.
骨具有在受伤后再生的固有能力。然而,大而复杂的骨折超出了骨的自然修复能力,导致骨折不愈合,需要外部干预来促进再生。一种潜在的治疗方法是组织工程骨移植物,它主要是通过重新形成膜内成骨(成骨细胞形成骨)来实现的,尽管大多数严重的骨损伤是通过软骨内成骨(通过肥大软骨原基的重塑形成骨)来愈合的。该领域已经证明,使用软骨内成骨为基础的策略可以导致骨沉积。然而,干细胞分化的肥大软骨细胞是软骨内成骨的关键细胞类型,尚未对其进行长骨缺损修复的研究。考虑到翻译,我们使用人脂肪干细胞(ASC)创建了组织工程移植物,这是一种临床相关的干细胞来源,在去细胞化骨支架中分化为肥大软骨细胞,并将这些移植物植入无胸腺大鼠的股骨临界缺损中。在植入的 12 周内,将这些移植物与无细胞支架和使用 ASC 衍生的成骨细胞构建的移植物进行了比较。使用肥大软骨细胞构建的移植物重现了软骨内成骨,这表现在与骨形成相关的基因和蛋白质的表达上。明显增强的骨沉积与广泛的骨重塑和骨髓的形成以及肥大移植物内具有促再生功能的 M2 巨噬细胞的存在有关。结果,肥大软骨细胞移植物桥接了 7/8 的缺损,而成骨细胞移植物仅桥接了 1/8,无细胞支架桥接了 3/8。这些数据表明,成骨支架中 ASC 衍生的肥大软骨细胞可以改善长骨修复。